Definitive Contract 75F40120C00179
Award Date 9/25/20
Potential Completion Date 6/30/24
Potential Value $1.6M
Federal Agency
Awardee
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
Durham, NC 27708, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
12
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Food and Drug Administration (FDA) has awarded a $1,567,108.00 definitive cost-no-fee contract to Duke University to conduct a study on Medicare Advantage for real-world evidence in cardiovascular disease. The contract has an ultimate completion date of September 29, 2026. Duke University, a prominent private research university, will be the prime contractor for this effort, which is not set aside under any special program. The contract award indicates Duke University's extensive...
- This is a $1,206,589.24 firm fixed-price contract awarded by the Food and Drug Administration (FDA) to Duke University's Office of Research Administration Division. The contract is for research and development to quantify patient priorities for clinical evidence on the impact of osseointegrated limb prostheses. This award was made under the FDA's Broad Agency Announcement for regulatory science and innovation research, with no set-aside designation. Duke University has previously received...
- This is a definitive contract awarded by the Food and Drug Administration (FDA) to Duke University in the amount of $1,046,733.02. The contract is for the "USE OF ELECTRONIC HEALTH RECORDS AS SOURCE DATA FOR CLINICAL RESEARCH" and has an ultimate completion date of December 28, 2020. The contract has a cost-no-fee pricing type and was not set aside for any socioeconomic program. Duke University, through its Office of Research Administration Division, is the prime contractor on this...
- Duke University Office of Research Administration Division was awarded a $274,413 definitive contract by the Department of Health and Human Services Food and Drug Administration to conduct a study using electronic health records to identify and assess adverse events for biologic therapies. The contract aims to develop and validate methodological approaches under the agency's Broad Agency Announcement for the Advanced Research and Development of Regulatory Science, which seeks proposals to...
- The Food and Drug Administration (FDA) has awarded a $749,661.00 firm fixed-price definitive contract to Duke University, a prestigious private research institution located in Durham, North Carolina. The contract is not set-aside and was issued under the FDA's Fiscal Year 2025 Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science. The BAA solicits basic and applied research and development proposals to support the FDA's mission of protecting and promoting...
- This is a $500,000.00 firm fixed price delivery order awarded by the Agency for Healthcare Research and Quality (AHRQ) to Duke University. The contract is part of the Evidence-based Practice Centers V (EPC V) program, which focuses on developing treatment strategies for patients with lower extremity peripheral venous disease. The contract has no set-aside designation. Duke University's Office of Research Administration Division is the prime contractor. The contract demonstrates Duke's capability...
- Duke University has been awarded a firm fixed price purchase order totaling $22,137 by the Department of Health and Human Services Food and Drug Administration. The contract is for technical expertise in predictive toxicology for drug-induced liver injury to be delivered through April 2025 in Durham, North Carolina. As the prime contractor, Duke University will provide technical expert services through its Office of Research Administration to support the FDA's predictive toxicology programs....
- This is a $1,056,338 firm fixed-price definitive contract awarded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to Duke University on behalf of the Duke Clinical Research Institute (DCRI). The contract's objective is to establish a partnership to enhance innovation in decentralized clinical studies and healthcare delivery models. This award was...
- This $79,869 firm fixed-price purchase order was awarded by the Food and Drug Administration (FDA) to Trustees of Dartmouth College, a private non-profit university, to conduct a retrieval analysis study on modern UHMWPE (ultra-high molecular weight polyethylene) medical devices. The purpose is to identify the most recent observations and mechanisms of in vivo oxidation. This contract is not set aside for any special designation. As the prime contractor, Dartmouth College will leverage its...
- This federal contract award, valued at $1,023,583.40, was issued by the National Institute of Child Health and Human Development (NICHD), a civilian agency, to Duke University as the prime contractor. The contract is for delivery of "FUROSEMIDE II" services, with a completion date of May 28, 2020. The contract does not have a set-aside designation. As part of this contract, Duke University has awarded two subcontracts: one to OPANS LLC for bioanalysis testing services, and another to...